A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes

    November 2025 in “ Journal of Clinical Medicine ”
    Sara Lambiase, Danilo Cavalloro, Arnaldo Cioni, Enrico Matteini, Fabio Artosi, Francesca Poscente, Riccardo Belardi, Alessandro Terrinoni, Sergio Bernardini, Luca Bianchi, Elena Campione, Laura Diluvio, Sara Lambiase, Danilo Cavalloro, Arnaldo Cioni, Enrico Matteini, Fabio Artosi, Francesca Poscente, Riccardo Belardi, Alessandro Terrinoni, Sergio Bernardini, Luca Bianchi, Elena Campione, Laura Diluvio
    TLDR Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
    This 52-week study assessed the efficacy and safety of baricitinib in 23 patients with moderate to severe alopecia areata (AA), showing significant hair regrowth with a decrease in the Severity of Alopecia Tool (SALT) score from 83.66 to 42.41. Patient-reported outcomes indicated improvements in quality of life and psychological well-being, with reductions in Skindex-16 and Hospital Anxiety and Depression Scale (HADS) scores. Trichoscopic assessments revealed a decrease in black and yellow dots and an increase in vellus hairs. Adverse effects were noted in 18.75% of patients, including genital candidiasis and menstrual irregularities. Despite these side effects, baricitinib was effective and had a favorable safety profile, supporting its use as a treatment for AA, though larger studies are needed for confirmation.
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results